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Abstract
Vernix caseosa is a white cream-like substance that covers the skin of the foetus and the newborn
baby. Recently, we discovered antimicrobial peptides/proteins such as LL-37 in vernix, suggesting
host defence functions of vernix. In a proteomic approach, we have continued to characterize
proteins in vernix and have identified 20 proteins, plus additional variant forms. The novel
proteins identified, considered to be involved in host defence, are cystatin A, UGRP-1, and
calgranulin A, B and C. These proteins add protective functions to vernix such as antifungal
activity, opsonizing capacity, protease inhibition, and parasite inactivation. The composition of the
lipids in vernix has also been characterized and among these compounds the free fatty acids were
found to exhibit antimicrobial activity. Interestingly, the vernix lipids enhance the antimicrobial
activity of LL-37 in vitro, indicating interactions between lipids and antimicrobial peptides in
vernix. In conclusion, vernix is a balanced cream of compounds involved in host defence,
protecting the foetus and newborn against infection.
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Introduction
Intra-amniotic infections are believed to be a trigger for miscarriage and preterm labour [1,
2]. The ability of the immunologically naïve foetus to avoid infections indicates strong
innate defence mechanisms that offer physiological protection before adaptive immune
responses are developed. During the last trimester of pregnancy, a protective biofilm, vernix
caseosa (vernix), is formed on the foetal skin. Vernix is a creamy white deposit derived from
the stratum corneum, sebaceous glands, and remnants of the epitrichium. The composition
of vernix is mainly water (80.5%), lipids (10.3%), and proteins (9.1%) [3]. It has been
debated for decades if vernix, together with the amniotic fluid, acts as a mechanical and
chemical barrier that protects foetuses against infectious pathogens [4, 5]. However, the
nature of the potentially active vernix compounds has been unknown.
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Recently, a number of antimicrobial peptides and proteins has been identified in vernix
[6-8]. Antimicrobial peptides and proteins are considered to be significant in the first line of
host defence in organisms ranging from plants to mammals [9]. The main families of
mammalian antimicrobial peptides, the cathelicidins and the defensins [10, 11], are
represented in vernix together with the well-known defence proteins lysozyme, lactoferrin,
secretory leukocyte protease inhibitor (SLPI), and psoriasin [6, 7]. Furthermore, vernix is
rich in lipids derived from the sebaceous glands. The microbicidal effects of a variety of
natural lipids have been extensively studied in recent years. A number of free fatty acids and
their 1-monoacylglycerols have been found to kill enveloped viruses and various bacteria in
vitro [12-15]. Like antimicrobial peptides, these active lipids affect cellular plasma
membranes [12, 16] and are widespread as defence effectors in tissues exposed to microbes
[9, 17-19]. In addition, breast milk has been shown to contain both antimicrobial lipids and
peptides [18, 20-22].
The microenvironment, including ionic strength, ionic composition, and pH, has
considerable influence on the activity of different antimicrobial peptides [23, 24].
Furthermore, synergy has been demonstrated between antimicrobial peptides and proteins,
e.g. between the human cathelicidin LL-37 and lactoferrin [25] and between specific
antimicrobial peptides [26, 27]. On the other hand, surfactants partly block the microbicidal
activity of LL-37 [28].
In this study, we have identified a variety of protein and lipid components of vernix,
including important components regarding host defence. In addition, the combined
bactericidal activity of LL-37 and the lipids of vernix was examined, indicating a
cooperative activity. Finally, we investigated the frequency of microbial colonization of
babies at the time of birth, and analysed the individual variation of the antimicrobial activity
found in vernix.
Material and methods
Collection of Vernix caseosa
Vernix caseosa was collected from the skin of newborns shortly after delivery, before any
washing of the neonates. The vernix samples were placed in sterile plastic containers and
were immediately frozen and stored at −20°C until analysed. All newborns were without
prenatal or perinatal complications, without clinical signs of infection.
Peptide/protein extraction
The vernix samples were homogenized in 60% acetonitrile containing 1% (v/v)
trifluoroacetic acid (TFA) using a POLYTRON® homogeniser (Kinematica AB, Littau,
Switzerland), and were extracted during shaking over night at 4°C. After centrifugation of
the extracts at 10.000 g, the supernatants were lyophilised. The lyophilised material was
dissolved in 0.1% (TFA) and loaded onto OASIS HLB cartridges (Waters, Milford, MA,
USA), which had been activated with acetonitrile and equilibrated in 0.1% aqueous TFA.
After the weakly bound material had been washed away with 0.1% aqueous TFA and 10%
acetonitrile in 0.1% TFA, bound proteins were eluted with 80% acetonitrile in 0.1% TFA
and the eluate was lyophilised.
Identification of proteins
Samples were separated and analysed by SDS-PAGE in 10-20% tricine gels (Invitrogen,
Carlsbad, CA, USA) at 125 V for 90 min. Protein bands were visualized by silver staining
using Silver Xpress (Invitrogen) according to the manufacturer's instructions. In further
SDS-PAGE runs proteins/peptides were transferred from the tricine gel onto a PVDF
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membrane for 70 min at 25 V. Proteins on the membranes were visualized after staining for
4 min with 0.1% Coomassie brilliant blue R-250 in 45% methanol/0.35 M acetic acid,
destaining for 5 min in 90% methanol/0.35 M acetic acid, and finally washed in water. The
stained protein bands were cut out from the membrane, and N- and C-terminal sequences
were determined chemically, utilizing PE-ABI Procise 494 cLC or 5HT 494 protein
sequencers and an ABI 494C instrument (Applied Biosystems, Foster City, CA, USA),
respectively.
In-gel digestion and protein fingerprinting
After electrophoresis, the tricine gels were fixed for 3 × 30 min in 2% phosphoric acid in
30% ethanol, washed for 3 × 20 min in 2% phosphoric acid, and equilibrated for 30 min in
equilibration buffer (2% phosphoric acid/5% aluminium sulphate/10% ethanol). The gels
were then stained for 2 h in 0.01% Coomassie brilliant blue G-250 in equilibration buffer,
and destained for 2 × 1 min in water. Protein bands were excised manually from the
Coomassie stained gels. The gel pieces were digested with trypsin using a MassPREP
robotic protein handling system (Micromass/Waters), employing a protocol previously
described [29]. Tryptic fragments were analysed by matrix-assisted laser desorption/
ionisation mass spectrometry (MALDI MS) (Voyager DE-Pro, Applied Biosystems), using
α-cyano-4-hydroxycinnamic acid as matrix (saturated in 70% acetonitrile) and mixed 1:1 (v/
v) with the sample. Database searches were carried out utilizing the ProteinProspector MS-
Fit program (http://prospector.ucsf.edu/). Peptides in chromatographic fractions were
analysed for their molecular masses by MALDI MS in the same manner as above.
High performance liquid chromatography (HPLC) of vernix extracts
Extracts were separated by reversed phase (RP) chromatography on an ÄKTA purifier
system (Amersham Pharmacia Biotech, Uppsala, Sweden) with an RPC Source™ 4.6/150
(Amersham Pharmacia Biotech) column, equilibrated in 0.1% aqueous TFA. Elution was
performed at a flow rate of 1 ml/min, and a gradient of acetonitrile from 0% to 15% in 5
min, 15% to 60% in 42 min, and 60% to 80% in 12 min was employed. The effluent was
monitored at 214 and 280 nm. Fractions were lyophilised and redissolved in 30 μl 0.1%
TFA before further analyses.
Microbial strains and culture conditions
Bacillus megaterium strain Bm11, Escherichia coli strain D21, group B Streptococcus
(GBS), a clinical isolate verified by Phadebact Strep B test (Boule Diagnostic AB,
Huddinge, Sweden), and Candida albicans (ATCC 14053) were utilized in a screening assay
to monitor the antimicrobial activity of the vernix extracts. Prior to each experiment,
microbial cells were seeded from frozen stocks (−70°C) onto agar plates, in Luria Bertani
(LB) medium (GibcoBRL, Life technologies, Paisley, Scotland) for the bacterial strains, and
in YM medium (Difco Laboratories, Detroit, MI, USA) for the yeast strain. The agar plates
were incubated over night at 37°C. Bacterial colonies were then picked from the plates and
suspended in LB broth, while yeast cells were suspended in YM broth, and both types of
cultures were incubated at 37°C under shaking, until desired cell density was reached.
Inhibition zone assay
Thin plates (1mm) of 1% agarose containing 6 × 104 bacterial cells/ml were prepared in LB
medium supplemented with medium E [30]. The assay for C. albicans was performed in the
same manner except that YM medium was used. Wells of 3 mm in diameter were punched
in the agarose layer, and samples in 3 μl 0.1% TFA were loaded into each well. After
overnight incubation at 37°C for GBS, and 30°C for all other microbes, inhibition zone
diameters were recorded.
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Lipid extraction
A lipid extract of vernix was obtained by the method described by Folch et al. [31], using
1.3 g vernix homogenized in a Potter-Elvehjem homogenizer (Kontes, Vineland, NJ, USA)
with a chloroform:methanol mixture (2:1, v:v) containing butylated hydroxytoluene (BHT; 5
mg/100ml) as antioxidant. After one hour shaking at room temperature, and centrifugation at
3000 rpm for 10 min, methanol and saline were added to the liquid phase (final ratio;
chloroform:methanol:saline, 1:1:0.8, v:v:v) and re-extraction was carried out followed by
centrifugation. The chloroform phase was evaporated with N2 and the total lipids were
dissolved in chloroform and stored at −30°C.
Thin-layer chromatography (TLC)
Lipid extract (30 mg) was separated on thin-layer plates (Adsorbosil soft layer, Alltech,
Deerfield, IL, USA) using a mobile phase of petroleum ether/diethyl ether/acetic acid
(80:20:1, v:v:v). The lipid components were visualized with 10% Rhodamine 6G in distilled
water and then scraped from the plate and transferred into centrifuge tubes, in which they
were extracted twice with hexane. The two hexane extracts were combined and the solvents
were evaporated with N2. Each lipid extract was then dissolved in 23 μl of chloroform and
analysed for antimicrobial activity utilizing a modified inhibition zone assay (see below).
Gas chromatography (GC)
The free fatty acids were converted into fatty acid methyl esters by incubation in 14% boron
trifluoride/methanol (Sigma Chemical Co., St. Louis, MO, USA) for 45 min at 110°C. The
methyl esters were analysed by high resolution gas liquid chromatography (Agilent 6890 N,
Agilent Technologies, Palo Alto, CA, USA) equipped with a flame ionization detector and a
Chrompack CP-WAX 52 CB polyethylene glycol column (25 m × 0.32 mm i.d × 0.2 μm).
Injector and detector temperatures were maintained at 235°C and 250°C, respectively. The
oven was programmed to have an initial temperature of 90°C for 2 min, then raised to 165°C
by 30°C /min, and to 225°C by 3°C /min, and finally held isothermal for 6 min. The carrier
gas was hydrogen at 31.8 kPa. Peaks obtained were identified and calibrated against those of
standards (Nu-Chek-Prep, Sigma, Elysian, MN, USA).
Modified inhibition zone assay
A modified inhibition zone assay was developed for the screening of lipid components
separated by TLC, and to evaluate interaction between the total lipid fraction of vernix and
the human cathelicidin LL-37. B. megaterium was used as the test organism. The samples
were loaded on top of the agarose (without use of wells) at 4°C. Lipid stock (∼ 650 g/l) was
made and diluted to the desired concentration in chloroform. A solution of the human
cathelicidin LL-37 (2 g/l) was prepared in chloroform containing 0.7 % TFA, giving a turbid
solution. The LL-37 solution, mixed in a 1:1 ratio with different dilutions of the lipid stock,
gave final lipid concentrations of ∼ 300, 30, 7, 3, and 0.3 g/l, in chloroform containing
0.35% TFA. Each peptide-lipid sample (3 μl) was loaded onto the agarose plates and
incubated overnight at 30°C. The inhibition zones (mm) were analysed by two-tailed Mann-
Whitney's U test. The differences in activity were regarded significant when the p-value
were less or equal to 0.05.
Colonization analysis
Immediately after birth samples were collected from the auditory canals, the axillae, and the
groins of newborn babies using a sterile cotton-tipped pin (Copan® sterile transport swab,
Brescia, Italy), and cultured for microbes by plating less than 12 h after collection according
to standard procedures.
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Results
Identification of proteins in vernix
Proteins/peptides were extracted from vernix (3 g) combined from 8 neonates. Utilizing
silver stained SDS-PAGE the pattern revealed 6 abundant protein bands (fig. 1). Vernix
extracts from 10 newborn individuals analysed in the same manner showed similar patterns
of abundant proteins (1-10 in fig. 1). However, the levels of the proteins vary between the
extracts. After transfer of the proteins to a PVDF membrane, 5 of the 6 proteins were
identified by N-terminal sequence analysis as haemoglobin α-chain, cystatin A (stefin A),
calgranulin A (S100A8, MRP-8, p8, L1 light chain), ubiquitin, and uteroglobin related
protein 1 (UGRP-1) (SCGB3A2, HIN-2) (fig. 1 and table 1). The cystatin A identified was
found to lack the N-terminal methionine, as has been shown to be characteristic of cystatin
A of epidermal origin [32]. Further characterization involved C-terminal sequence analysis
of haemoglobin α and UGRP-1 (table 1), as well as peptide mass fingerprinting after in gel
digestion (on sample number 8, fig. 1). By the latter method, 3 more variants of UGRP-1
were identified (table 1), in addition to haemoglobin chain, lysozyme C, haemoglobin γ
chain, psoriasin (S100A7), calgranulin B (S100A9, MRP-14, p14, L1 heavy chain), and
caspase 14 precursor (table 1).
The protein/peptide extract of the combined vernix sample from 8 neonates (fig. 1) was
separated by RP HPLC (fig. 2), and proteins in fractions were further characterized by direct
sequence analysis (table 1) and MALDI MS. In fractions corresponding to peak 10 (fig. 2),
all UGRP-1 variants were identified. In addition, after separation on SDS-PAGE and
blotting onto a PVDF membrane, several more proteins were identified by N-terminal
sequence analysis (table 1). These were apolipoprotein C-1, apolipoprotein A-II, calgranulin
C (S100A12), UGRP-2 (SCGB3A1 /HIN-1), profilaggrin, lymphocyte antigen Ly6E,
squamous cell carcinoma antigen 1 and/or 2, transthyretin, and the hypothetical protein
FLJ40379. The mass spectrometric analyses on the fraction corresponding to peak 1 in fig. 2
revealed three different masses for ubiquitin corresponding to variant C-terminal forms
(table 1).
Lipid composition of vernix and antibacterial activity
The Folch extract of vernix was separated on TLC (fig. 3), detecting eight zones which were
identified as, wax esters/sterol esters/squalene, triacylglycerol, free fatty acids, fatty
alcohols, cholesterol, diacylglycerol, monoacylglycerol, and phospholipids. The hexane
extract of the TLC zone containing free fatty acids was the only lipid fraction that exhibited
antibacterial activity against B. megaterium (Bm11), giving a diameter of 1.7 mm in the
modified antibacterial assay. The relative fatty acid composition of the free fatty acid zone
was determined by gas chromatography (table 2), showing that 50.1% was saturated fatty
acids, C16:0, C22:0, and C24:0 being the most abundant. The major mono- and
polyunsaturated fatty acids were C16:1, C18:1, C18:2, and C22:4 (table 2). No short or
medium chain acids (4 to 12 carbons) were identified.
Bactericidal interactions of LL-37 and vernix lipids
To investigate whether LL-37 and the vernix lipids interact with each other, and hence affect
the antibacterial activity, we developed a modified inhibition zone assay. Different
concentrations of the vernix lipid fraction were prepared and mixed with 3 μg LL-37 in
choloroform with 0.35% TFA. An inhibition zone of 3.6 mm in diameter was recorded for 3
μg of LL-37 alone (control in fig. 4), while a zone diameter of 1.5 mm was observed for the
highest concentration of lipids alone. In contrast, neither the other lipid concentrations, nor
the negative control (chloroform with 0.35% TFA) exhibited any activity. Notably, the
activity of 3 μg LL-37 was enhanced when mixed with lipids in certain proportions (fig. 4).
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A maximum of 5.6 mm in zone diameter was recorded at a lipid:peptide ratio of 3:1. The
antibacterial activity of samples with a ratio of 3:1 and 7:1 was significantly increased
versus that with LL-37 alone, p = 0.005 and p = 0.031, respectively.
Identification of chlorhexidine in vernix
The highest activity against both E. coli and GBS was recorded in fractions corresponding to
peak 2 (fig. 2). The component giving rise to this activity was isolated by two consecutive
RP chromatographic steps, utilizing Vydac C18 (4.6 × 250) mm and C8 (2.1 × 150) mm
columns (The Separations Group, Hesperia, CA, USA), respectively. The active component
eluted at 38.6% acetonitrile in the first run using 0.1% heptafluorobutiric acid as a counter-
ion, and at 32.4% acetonitrile in the second run using 0.1% TFA as a counter-ion. This
component gave rise to symmetric absorbancy peaks at both 214 nm and 280 nm. Utilizing
nanoelectrospray mass spectrometry in the positive ion mode, the isotopic composition of a
cluster of protonated molecules at m/z 505 indicated the presence of two chlorines in the
compound. The accurate molecular mass 504.203 obtained at a working resolution of
∼15500 (full-width at half maximum) was used to calculate possible elemental compositions
and to search in the database registry created by Chemical Abstract Service (CAS), hosted
by the Scientific & Technical Information Network (STN) in Karlsruhe, Germany. One
alternative (C22H30Cl2N10) corresponded to the antimicrobial substance clorhexidine.
Comparison of the collision-induced dissociation spectrum with that of authentic
chlorhexidine showed that the compound was chlorhexidine.
Antimicrobial activity in protein/peptide extracts of vernix
Vernix samples were collected from 88 neonates, and peptides and proteins extracted from
each sample. The extracts were screened for antimicrobial activity against four different
microbial species, i.e. B. megaterium (71 samples), E. coli (86 samples), GBS (88 samples),
and C. albicans (81 samples). All samples analysed exhibited activity against C. albicans
and B. megaterium, while 78% were active against GBS and 31% against E. coli (fig. 5).
The highest activity was recorded against B. megaterium and GBS, an average of 8.4 and
8.3 mm zone diameters, respectively. Intermediate activity was obtained against C. albicans
(7.3 mm), and the lowest activity was recorded against E. coli (5.6 mm). High variation of
antibacterial activity was observed against all bacteria. In contrast, low variation in
antifungal activity was noted against C. albicans. The samples exhibiting activity against E.
coli, (× in fig. 5), are clustered in the higher activity range against both GBS and B.
megaterium. However, samples active against E. coli (×) have similar activity distribution
against C. albicans as the samples that exhibit no activity against E. coli (fig. 5), showing
different origin of the antibacterial and antifungal activities in vernix.
Fractions from the RP chromatography (fig. 2) were screened for antibacterial activity
against GBS and E. coli (fig. 2). Anti-streptococcal activity was detected in fractions
distributed over more than half of the chromatogram, which indicates that many different
components in vernix are responsible for this activity. On the other hand, the activity against
E. coli was found in a much narrower range, only in fractions corresponding to peak 1 and 2
(fig. 2). As explained above the most active component in these fractions is chlorhexidine.
This indicates that chlorhexidine is the major contributor of total E. coli activity, and that
vernix samples found active against E. coli are possibly contaminated by higher levels of
chlorhexidine than samples with no E. coli activity. In samples active against E. coli, a part
of the high activity against B. megaterium and GBS is concluded to originate from
chlorhexidine. Notably, if we exclude the E. coli active samples (marked × in fig. 5), the
activity range against B. megaterium decreases remarkably, while the activity range against
GBS is still high.
Tollin et al. Page 6
Cell Mol Life Sci. Author manuscript; available in PMC 2008 April 17.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Microbial colonisation of newborns
Immediately after birth, samples were collected from the skin surface of 87 newborn babies
for detection of microbial colonization of the skin. Fourteen groups of bacteria were found
to colonize the surface of the babies. Only one baby was not colonized with any bacteria, 26
(31%) babies were colonized with one group of bacteria, 34 (40%) were colonized with two
groups, 20 (24%) were colonized with three groups, and two (2%) were colonized with four
groups. Staphylococcus (coagulase negative) colonized 86% of the babies, Bacillus sp. 27%,
and E. coli 21%. Only 4% of the babies were colonized with GBS, and 2% with C. albicans
(table 3).
Discussion
In previous studies, we have characterized antimicrobial peptides and polypeptides in vernix
[7, 8]. In the present study we demonstrate the presence of many more proteins of
immunological importance in vernix. Among the most abundant proteins now characterized
are cystatin A, calgranulin A, ubiquitin, and UGRP-1, which are all implicated in innate
immunity of humans. Vernix lipids were now also characterized in which antimicrobial
activity was detected, in particular for free fatty acids. In addition, our results indicate that
lipids may contribute to a favourable microenvironment in vernix by interacting with
antimicrobial components such as LL-37. Our characterization of proteins, lipids and their
interactions suggest that vernix is a complex innate defence barrier, protecting the foetus and
the newborn from infectious microbes, in an apparently crucial manner, since the adaptive
immunity of newborns is immature. The antimicrobial property of vernix may also act to
facilitate colonization by the normal flora following birth and to block the colonization of
unwanted microbes or pathogens. For example psoriasin, which is identified in vernix,
directly kills E. coli but not Staphylococcus aureus [33, 34]. The shedding of the vernix in
late pregnancy may suggest that the level of protection has to be adjusted to allow proper
colonization of the normal flora.
Several proteins now identified are expressed in skin such as cystatin A, profilaggrin,
psoriasin and calgranulin C. Due to the close contact of vernix and amniotic fluid, they share
some of the same components. This is now shown regarding calgranulin A and B, proteins
previously known to be present in amniotic fluid [35]. The origin of UGRP-1 may be the
lungs, and a transfer of this protein to vernix may occur via the amniotic fluid. Blood may be
another source of the identified proteins in vernix. Using mass fingerprinting, we identified
not only α- and β- haemoglobin but also γ-haemoglobin. During the last two trimesters of
pregnancy the foetus produces γ-haemoglobin, which is replaced by β-haemoglobin after
birth, enabling an efficient transfer of oxygen from the blood of the mother to the foetus.
Thus, the γ-haemoglobin detected in vernix originates from the foetus.
Calgranulin A, B, and C, and psoriasin all belong to the S100 family of calcium binding
proteins. The S-100 family of proteins has 2 calcium binding motifs of the EF-hand type
[36]. These proteins have been shown to exhibit chemotactic properties and may play a role
in the pathogenesis of epidermal diseases [36]. Notably, an N-terminal fragment of
profilaggrin, with sequence similarity to the two EF-hands [37], was also identified in
vernix.
Calprotectin is an antifungal and antibacterial complex consisting of a heterodimer of
calgranulin A and calgranulin B [38]. Both subunits were identified, revealing that the active
holoprotein is present in vernix. Accordingly, the crude peptide/protein extract of vernix
exhibited good antifungal activity. However, after separation of the protein extract by RP-
HPLC we could not detect any antifungal activity in the collected fractions (data not shown).
Our interpretation of this difference is that the two subunits of calprotectin have been
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separated upon HPLC, leading to loss of activity. Calprotectin is suggested to kill microbes
by chelating zinc, thereby depriving microbes of an essential metal ion [39]. This mode of
action has also been described for lactoferrin and psoriasin, the latter being a major E. coli-
killing compound in human skin [33].
Calgranulin C was first identified on the surface of onchoceral worms in human
subcutaneous nodules [40]. It is proposed to be released by activated neutrophils and thereby
attack and kill nematodes [40]. Thus, the presence of calgranulin C in vernix contributes to
the protective role of vernix.
Cystatin A is a protease inhibitor that is mainly expressed by epithelial and
polymorphonuclear cells [41, 42]. Cystatin A is also a minor cross-linking component of the
cornified cell envelope [43] and a part of the mechanical barrier of the skin. Unlike cystatin
C, cystatin A has not been shown to possess any direct antimicrobial effect. However,
cystatin A has been suggested to be a first line protector against cysteine proteases released
from infectious micro-organisms and parasites [44]. Thus, cystatin A could have a dual role
in the innate defence of the foetus.
Our results reveal that UGRP-1 (HIN-2/SCGBA2) is one of the major proteins in vernix,
whereas UGRP-2 (HIN-1 /SCGBA1) is not as abundant. These proteins are both expressed
at high levels in neonatal lungs by different subsets of secretory cells within the surface and
glandular epithelia [45]. UGRP-1 has been shown to bind bacteria and to the macrophage
scavenger receptor MARCO [46], indicating opsonizing properties. In the lungs of mice the
expression of UGRP-1 is upregulated by IL-10 [47], while it is downregulated by IL-5 [48],
suggesting that UGRP-1 is a target of anti-inflammatory pathways. In vernix, we have
characterised three novel forms of UGRP-1, which are N-terminally differently processed.
These forms may have altered binding affinities to bacteria, leading to enhancement of the
opsonizing spectra.
Vitamin A has been detected at high levels in vernix [49] and is proposed to serve as a
nutritional depot of vitamin A. Vitamin A is secreted from the amniotic epithelium into the
amniotic fluid, and is taken up by vernix [49]. Our results show that transthyretin is present
in vernix, a protein that binds to the retinol binding protein, which in turn binds vitamin A.
Like lipids previously isolated from human stratum corneum and sebum [50, 51], our results
demonstrate inhibitory effects of the free fatty acids in vernix against the Gram-positive
bacterium B. megaterium. We also demonstrate that palmitoleic acid (C16:1) and linoleic
acid (C18:2), known to exhibit potent antimicrobial activity [14, 52], are a considerable part
of the total free fatty acids. The long-chain unsaturated fatty acids found in vernix (C20 to
C22 in table 2) are also antimicrobial and the activity is enhanced with an increase of the
number of double bonds [15]. Like antimicrobial peptides [53], fatty acids and
monoacylglycerols disintegrate the lipid envelope of viruses [15] and bacterial plasma
membranes [12, 16].
Considering the high lipid content of vernix (10%) [3], it seems possible that lipids influence
the function of other components of vernix. It has been demonstrated that other factors such
as salts and pH, influence the conformation of the human cathelicidin LL-37 [23]. Therefore
we speculate that the lipid fraction of vernix can exhibit similar functions. Under our
experimental conditions, lipids isolated from vernix enhanced the antimicrobial potency of
LL-37. Thus, LL-37 can be active in a lipid-rich environment.
When studying the antimicrobial activity in peptide/protein extracts of vernix, we found a
high antimicrobial activity against bacteria and fungi. The most active antibacterial
compound against E. coli and GBS in these samples was isolated and identified as
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chlorhexidine. Chlorhexidine is a microbicidal substance of vaginal cream used as a
lubricant during vaginal examination prior to delivery. For this reason, some of the vernix
samples were found to contain chlorhexidine. We noted that the samples with E. coli activity
(labelled x in fig. 5) also exhibited activity against B. megaterium and GBS. Since we
demonstrated that the main component active against E. coli was chlorhexidine, we
speculated that high E. coli activity indicates higher degree of chlorhexidine in these
samples. To minimize the contribution of chlorhexidine we excluded the samples active
against E. coli from the analyses. This showed that the interindividual variation of activity is
high against GBS and lower against B. megaterium and C. albicans. Similarly the
colonisation data could also be affected by chlorhexidin. However, when the E. coli positive
samples were removed, only small differences in colonisation were observed (data not
shown).
In conclusion, we have characterized proteins and lipids that add novel protective functions
to vernix, such as antifungal properties, opsonizing features, protease inhibiton, and parasite
inactivation. In addition, the antimicrobial action of LL-37 can be potentiated by the lipids
in vernix in vitro, stressing the importance of the microenvironment for the function of
antimicrobial components.
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Figure 1.
Gel electrophoresis of proteins in vernix caseosa. Peptide/protein extracts (5 μg) from 10
individual babies (nr1-10), and from a vernix mixture of eight babies (mix), were separated
by SDS-PAGE and visualised by silver staining. The proteins in the major bands were
identified by N-terminal sequence analysis after transfer of the proteins from a preparative
gel to a PVDF membrane, and are indicated to the right. SM; size marker.
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Figure 2.
Protein separation and antimicrobial activity. HPLC separation of 4.5 mg protein/peptide
extract originating from 8 neonates is shown in (A). After separation fractions were
dissolved in 30 μl 0.1% aqueous TFA and screened for activity against GBS and E. coli.
The activity is shown in panel (B), where the columns stand for the mm of inhibition zone
diameter.
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Figure 3.
Separation of the lipid extract of vernix, using thin-layer chromatography. The separated
lipid classes are indicated.
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Figure 4.
Bactericidal interactions of LL-37 and vernix lipids. LL-37 (3 μg) was mixed with different
amounts of vernix lipid extract in chloroform with 0.35% TFA. The lipid amount in the
samples is given as mass ratio (lipid:peptide). The positive control was the LL-37 peptide,
and the negative control was chloroform with 0.35% TFA. The experiments were repeated 4
times in duplicates, and Mann-Whitney U test used for the statistical analysis, ** p < 0.01 *p
< 0.05.
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Figure 5.
Antimicrobial activity of crude protein/peptide extracts of vernix against B. megaterium, E.
coli, GBS, and C. albicans. Extracts exhibiting activty against E. coli are marked with ×.
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Table 2
Fatty acid composition of vernix
Fatty acids % (weight/weight)
SFA 50.1
C14:0 2.0
C15:0 1.0
C16:0 14.0
C17:0 0.4
C18:0 2.0
C20:0 0.8
C22:0 5.4
C24:0 24.5
MUFA 11.4
C16:1n-9 2.0
C16:1n-7 1.3
C18:1n-9 6.4
C18:1n-7 1.7
PUFA 15.0
C18:2n-6 9.6
C20:2n-6 1.3
C22:4n-6 4.1
Unidentified 23.0
SFA, saturated fatty acids (FA); MUFA, monounsaturated FA; PUFA, polyunsaturated FA; Data are expressed as weight % of total fatty acids in
vernix; Values represent the average of two determinations
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Table 3
Frequency and type of bacterial colonisation of new borns at birth
Microbe Frequency of
colonization among 87
neonates (%)
Gram positive
Staphylococcus (coagulase negative) 75 (86%)
Staphylococcus aureus 4 (5%)
Lactobacillus sp. 1 (1%)
Corynebacterium 9 (11%)
Streptococci, viridans group 10 (12%)
Streptococci, haemolytic group G 1 (1%)
Streptococci, haemolytic group B 3 (4%)
Streptococci, non-haemolytic 5 (6%)
Bacillus sp. 23 (27%)
Bacillus subtilis 1 (1%)
Gram negative
Coliform bacilli 10 (12%)
E. coli 18 (21%)
Enterococcus 2 (2%)
Yeast
Candida albicans 2 (2%)
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